AbbVie, Teneobio to Develop Multiple Myeloma Treatment

Datum : 11/02/2019 @ 14h46
Quelle : Dow Jones News
Name : Abbvie Inc. (ABBV)
Kurs : 68.54  0.29 (0.42%) @ 01h59
AbbVie Inc. share price Chart

AbbVie, Teneobio to Develop Multiple Myeloma Treatment

AbbVie Inc. (NYSE:ABBV)
Historical Stock Chart

6 Monate : Von Jan 2019 bis Jul 2019

Click Here for more AbbVie Inc. Charts.
   By Colin Kellaher 

AbbVie Inc. (ABBV) on Monday said it reached an agreement with privately held biotechnology company Teneobio Inc. and its TeneoOne Inc. affiliate to develop and commercialize TNB-383B for the potential treatment of multiple myeloma.

The North Chicago, Ill., biopharmaceutical company said it will make a $90 million upfront payment to TeneoOne, which will continue developing TNB-383B through phase 1.

AbbVie said it will have the exclusive right to acquire TeneoOne and lead subsequent global development and commercialization of the immunotherapeutic.

AbbVie said TeneoOne's shareholders would also be eligible for regulatory and commercial sales milestones should AbbVie exercises its acquisition rights.

AbbVie said Teneobio will begin the clinical program for TNB-383B in the first half of 2019.


Write to Colin Kellaher at


(END) Dow Jones Newswires

February 11, 2019 08:31 ET (13:31 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Kürzlich von Ihnen besucht
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

Der Markt LS (Lang&Schwarz) wird als Realtime Indikation kostenlos angezeigt und bietet Ihnen außerbörsliche Realtime Aktienkurse in der Zeit von Mo-Fr 08:00 bis 23:00, Samstags 10:00 bis 13:00 und Sonntags an.
NYSE und AMEX Kurse sind um mindestens 20 Minuten zeitverzögert.
Alle weiteren Kurse sind um mindestens 15 Minuten zeitverzögert, sofern nicht anders angegeben.
P: V:de D:20190721 06:35:54